ANI Pharmaceuticals to Present at the Raymond James Human Health Innovation Conference 2021
Get Alerts ANIP Hot Sheet
Join SI Premium – FREE
BAUDETTE, Minn.--(BUSINESS WIRE)-- ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced that Nikhil Lalwani, Chief Executive Officer, and Stephen Carey, Chief Financial Officer, will present at the Raymond James Human Health Innovation Conference 2021 as follows:
Date: |
Tuesday, June 22, 2021 |
|
Time: |
12:00pm Eastern Time |
|
Webcast Link: |
https://kvgo.com/rj-health/ani-pharmaceuticals-inc-june-2021 |
The presentation will be webcast live at the aforementioned time, and archived for 30 days thereafter, via the Company’s website at www.anipharmaceuticals.com, under the Investors section.
About ANI
ANI Pharmaceuticals, Inc. is an integrated specialty pharmaceutical company focused on delivering value to our customers by developing, manufacturing, and marketing high quality branded and generic prescription pharmaceuticals. We focus on niche and high barrier to entry opportunities including controlled substances, oncology products (anti-cancers), hormones and steroids, and complex formulations. For more information, please visit our website www.anipharmaceuticals.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210615005369/en/
Investor Relations:
Lisa M. Wilson, In-Site Communications, Inc.
T: 212-452-2793
E: [email protected]
Source: ANI Pharmaceuticals, Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- ANI Pharmaceuticals Announces the Launch of Levofloxacin Oral Solution, USP
- Cushman & Wakefield Recognized by Newsweek as One of America’s Greatest Workplaces for Women
- InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Schedules Release of Q4 and FY 2023 Results, Conference Call
Create E-mail Alert Related Categories
Business Wire, Press ReleasesRelated Entities
Raymond JamesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!